VEEVA SYSTEMS INC Annual Report - How They Did This Year (Fiscal Year Ended January 31, 2026)

Hey there! Think of me as your guide to Veeva Systems' latest annual report. We'll break down what they've been doing. We'll also cover their financial health. And what it all means for you as a potential investor. No fancy jargon, just plain talk.

Good news! We have the full details from Veeva's annual report. It covers the fiscal year that just ended on January 31, 2026. Let's dive into their performance.

Company Snapshot

Veeva Systems is a pretty big player! As of July 31, 2025, Veeva was worth about $42.6 billion. This shows it's a major company. About 163.3 million Class A common shares were available as of March 17, 2026. This report confirms Veeva is a "well-known seasoned issuer" and a "large accelerated filer." This means it's a big, established company. They have a good public reporting history.

At its core, Veeva provides cloud-based software solutions. These are specifically for the global life sciences industry. They help pharmaceutical, biotech, and medical device companies. They manage everything from drug development to commercialization. Their business has two main parts:

• Veeva Commercial Cloud: This suite includes tools for customer relationships (CRM). It also handles content and data analysis. These help sales, marketing, and medical teams. They can better engage healthcare professionals. They also manage promotional materials. Key products include Veeva CRM, Veeva Vault PromoMats, and Veeva OpenData.
• Veeva Development Cloud: This segment offers tools for clinical operations, regulatory affairs, quality, and safety. It helps companies simplify drug development. This includes clinical trials, regulatory filings, and quality control. Examples include Veeva Vault Clinical Suite, Veeva Vault Quality, and Veeva Vault RIM.

Veeva makes most of its money from subscription services. These brought in about 84% of total revenue in fiscal year 2026. This gives them stable, regular income. The rest of their money comes from professional services. These include implementation, consulting, and training. They help customers use Veeva's solutions best.

Recent Developments

Just after the fiscal year ended, on March 10, 2026, Veeva announced a notable event. It involved Veeva Rise Healthcare Tech Inc. Ostro. This is a big strategic step for Veeva. Ostro is a new cloud platform. It will serve the wider healthcare industry. This goes beyond their usual life sciences focus. Veeva wants to use its expertise in regulated industries. This will help healthcare providers, payers, and others. It addresses their digital needs. This could drive major growth for Veeva. It opens up a much larger market for them.

Financial Performance (Fiscal Year Ended January 31, 2026)

Veeva reported strong financial results for fiscal year 2026:

• Total money brought in reached $2.80 billion. This was an 18% increase from $2.37 billion in fiscal year 2025.
• Subscription money, their main earner, grew 20% from last year. It hit $2.35 billion.
• Professional services money added $450 million. This was up 10% from last year.
• Gross profit was $2.15 billion. This means they kept 76.8% of their revenue after direct costs.
• Operating profit was $950 million. This means 33.9% of their revenue was profit before taxes and interest.
• Profit for the year was $750 million. This is a 25% increase from $600 million in fiscal year 2025.
• Profit per share was $4.59. This is based on 163.3 million shares. These shares include potential new ones.

Key Achievements and Challenges

Achievements:

• Veeva showed strong customer loyalty and growth. Existing customers spent 120% more than they did last year. This means they are buying more of Veeva's products.
• They successfully expanded their Veeva Development Cloud. New tools for clinical data and real-world evidence are popular. Pharmaceutical and biotech clients are using them more.
• Veeva also grew its customer base. They reached more emerging biotech and smaller pharma companies. This adds to their strong ties with large pharma.
• They added advanced Artificial Intelligence (AI) to the Vault platform. This improved data insights, automation, and efficiency for customers.

Challenges:

• Veeva faced more competition. This was especially true in clinical trial software. They must keep investing to make their products stand out and innovate.
• The company dealt with changing global data privacy rules. This meant ongoing efforts to comply. They also adjusted products to meet standards like GDPR and HIPAA.
• Economic uncertainties affected some customer spending. This was for R&D and commercial efforts. New deals took longer to close. Some customers also planned budgets cautiously.

Cash and Liquidity

Veeva has a strong financial position. They held $3.5 billion in cash and easy-to-sell investments. This was as of January 31, 2026. The company brought in an impressive $1.1 billion from its daily business. This shows strong underlying profit. It also shows efficient cash handling. They spent a modest $150 million on new equipment and buildings. This mainly went to data centers and office upgrades. Veeva also gave money back to shareholders. They bought back about $500 million of their own stock. This helped prevent your ownership percentage from shrinking due to new shares given to employees. The company has no major long-term debt. This gives them great financial flexibility and strength.

Principal Risks

Investors should be aware of several key risks:

• Regulatory Environment: The life sciences industry is heavily regulated. Changes from bodies like the FDA or EMA could affect drug development. This could then impact Veeva's customers. It could also reduce demand for Veeva's tools.
• Competition: Veeva faces strong competition. Large software companies like Salesforce, Oracle, or Medidata are rivals. Smaller, specialized vendors also compete. If Veeva doesn't innovate or keep its expertise, it could lose market share.
• Data Security and Privacy: Veeva handles sensitive patient data. This makes it a target for cyberattacks. A major data breach or not following privacy laws could be costly. It could also harm their reputation and customer trust.
• Customer Concentration: Veeva serves many customers. But a lot of its money comes from a few big pharma companies. Losing a major customer or their reduced spending could hurt Veeva's finances.
• Technological Obsolescence: Technology changes fast. Veeva must invest in R&D to keep its platforms competitive. If they don't adapt to new tech like AI, they could lose their market lead.

Competitive Landscape

Veeva faces competition. But it stands out with its deep expertise in life sciences. It offers complete cloud solutions just for this industry.

• In Commercial Cloud, Veeva competes with general CRM providers like Salesforce. Salesforce is also a partner for Veeva CRM. Other specialized sales tools also compete. Veeva's strength is its built-in compliance. It also has life sciences workflows and vast industry data.
• For the Development Cloud, rivals include Medidata Solutions and Oracle Health Sciences. Smaller companies offer specific tools for clinical, regulatory, and quality management. Veeva's Vault platform combines these functions. Many competitors don't offer this unified approach. Veeva's strategy is to expand its platform and deepen its focus on life sciences. This keeps its competitive edge. It also meets the unique needs of the sector.

Strategic Direction and Future Outlook

Veeva's strategy centers on innovation. They also want to expand their "cloud for life sciences" vision. This means big investments in research and development (R&D). They spent about 20% of their annual revenue in fiscal year 2026. This helps them improve products and create new ones. Key areas of focus include:

• Expanding the Veeva Development Cloud further. This includes clinical data management, real-world evidence, and advanced R&D analytics.
• Growing the Veeva Commercial Cloud. They will add new ways to connect and data tools. This helps commercial teams adapt to changing healthcare interactions.
• Scaling new initiatives like Veeva Link (for scientific info) and Veeva Pulse (for sales insights). This adds more value for customers.
• Expanding geographically, especially in new markets. This will gain new customers and make their offerings global. Veeva expects revenue to keep growing by 15-17% in fiscal year 2027. This comes from strong subscription renewals. New customers and more products will also help.

Industry Trends

The life sciences industry is changing fast. Companies are going through a digital transformation. They use more cloud solutions. This boosts efficiency, compliance, and speed to market. This trend strongly benefits Veeva.

• Personalized medicine and precision health are growing. This increases demand for advanced data tools. Veeva's platforms are well-suited to help here.
• Decentralized and hybrid clinical trials are becoming more common. This needs flexible, integrated tech solutions. Veeva's Vault Clinical Suite is actively meeting this need.
• AI and machine learning are now crucial. They speed up drug discovery. They also improve clinical trials and sales effectiveness. Veeva is adding AI to all its products.
• More global regulations and complexity continue. This drives demand for strong, compliant, and auditable systems. These manage key life sciences processes. This boosts the value of Veeva's specialized tools.